<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03880487</url>
  </required_header>
  <id_info>
    <org_study_id>KP-1199-CP-001</org_study_id>
    <secondary_id>CDMRP-OR 160158</secondary_id>
    <nct_id>NCT03880487</nct_id>
  </id_info>
  <brief_title>A Single and Multiple Ascending Dose Study in Healthy Subjects to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of KP-1199</brief_title>
  <official_title>A Randomized, Placebo- and Active-Controlled, Double-Blind, Single and Multiple Ascending Dose Study in Healthy Adults to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of KP-1199</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kalyra Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>PRA Health Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kalyra Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I, randomized, placebo and active-controlled, double blind, single and&#xD;
      multiple ascending dose study in healthy adults to evaluate the safety, tolerability,&#xD;
      pharmacokinetics and preliminary efficacy of KP-1199&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The Study was terminated early by sponsor&#xD;
  </why_stopped>
  <start_date type="Actual">March 12, 2019</start_date>
  <completion_date type="Actual">April 21, 2020</completion_date>
  <primary_completion_date type="Actual">April 21, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Treatment Emergent Adverse Events</measure>
    <time_frame>Part 1: From Day 1 through Day 6, Part 2: From Day 1 through Day 11, Part 3: From Day 1 through Day 12</time_frame>
    <description>Number of treatment related adverse events as determined by abnormal clinical laboratory tests, vitals signs, physical exam, ECG parameters</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Profile of KP-1199 to measure plasma concentration of KP-1199</measure>
    <time_frame>Part 1: Day 1 (pre-dose through 4 hours after dose administration), Part 2: (pre-dose through Day 8), Part 3: (pre-dose through Day 7)</time_frame>
    <description>Maximum Observed Plasma Concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Profile of KP-1199 to measure Time to Maximum plasma concentration of KP-1199</measure>
    <time_frame>Part 1: Day 1 (pre-dose through 4 hours after dose administration), Part 2: (pre-dose through Day 8), Part 3: (pre-dose through Day 7)</time_frame>
    <description>Time to Maximum Plasma Concentration (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Profile of KP-1199 to measure area under curve plasma concentration of KP-1199</measure>
    <time_frame>Part 1: Day 1 (pre-dose through 4 hours after dose administration), Part 2: (pre-dose through Day 8), Part 3: (pre-dose through Day 7)</time_frame>
    <description>Area Under the Concentration-time Curve Up to Time (t), where t is the last point with concentrations above the lower limit of quantitation (AUC0-t) Area Under the Concentration-time Curve for 1 dosing interval of a multiple dose regimen (AUCtau)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Profile of KP-1199 to measure plasma terminal half-life concentration of KP-1199</measure>
    <time_frame>Part 1: Day 1 (pre-dose through 4 hours after dose administration), Part 2: (pre-dose through Day 8), Part 3: (pre-dose through Day 7)</time_frame>
    <description>The Apparent Terminal Elimination Half-life (t1/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Profile of KP-1199 to measure the trough plasma concentration of KP-1199</measure>
    <time_frame>Part 1: Day 1 (pre-dose through 4 hours after dose administration), Part 2: (pre-dose through Day 8), Part 3: (pre-dose through Day 7)</time_frame>
    <description>Trough Plasma Concentration (Ctrough)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Effects of KP-1199 using Cold Pressor Test to measure pain threshold</measure>
    <time_frame>Part 3: Day 1, Day 3, Day 5 and Day 7 (pre-dose through 6 hours after dose administration)</time_frame>
    <description>Time to feel first pain (&quot;pain threshold&quot; measured in seconds)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Effects of KP-1199 using Cold Pressor Test to measure pain tolerance</measure>
    <time_frame>Part 3: Day 1, Day 3, Day 5 and Day 7 (pre-dose through 6 hours after dose administration)</time_frame>
    <description>Time to withdrawal of hand from cold water (&quot;Pain tolerance&quot; in seconds)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Effects of KP-1199 using Cold Pressor Test</measure>
    <time_frame>Part 3: Day 1, Day 3, Day 5 and Day 7 (pre-dose through 6 hours after dose administration)</time_frame>
    <description>Pain tolerance will be measured at time of hand withdrawal using a 11-point (0-10) Numeric Pain Rating Scale (NPRS) where &quot;0 (no pain) to 10 (worst pain)&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Effects of KP-1199 using Ultraviolet Burn Model (UVB)</measure>
    <time_frame>Part 3: Day 1, Day 3, Day 5 and Day 7 (pre-dose through 6 hours after dose administration)</time_frame>
    <description>Neurosensory Testing (change in neurosensory assessments of the skin at site of ultraviolet burn)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Analgesia</condition>
  <arm_group>
    <arm_group_label>KP-1199</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo oral capsules</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxycodone oral capsules</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KP-1199</intervention_name>
    <description>Single dose and Multiple ascending doses of KP-1199 oral capsules</description>
    <arm_group_label>KP-1199</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Single dose and Multiple dose identical to active treatment but without KP-1199.</description>
    <arm_group_label>Placebo oral capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone oral capsule</intervention_name>
    <description>10 mg Oxycodone Capsules</description>
    <arm_group_label>Oxycodone oral capsules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy Adult 18-45 years of age at time of screening, inclusive.&#xD;
&#xD;
          -  Have a body mass index (BMI) between 18.0 and ≤32 kg/m2, inclusive, and a weight of&#xD;
             ≥50 kg at screening.&#xD;
&#xD;
          -  Be determined to be healthy on the basis of a pre-study physical examination, medical&#xD;
             history review, vital sign measurements, and the results of laboratory tests.&#xD;
&#xD;
          -  For both male and females: using acceptable method of birth control&#xD;
&#xD;
          -  If Female: not-pregnant or not breast feeding and not planning on becoming pregnant&#xD;
&#xD;
          -  All prescribed medication must have been stopped at least 14 days prior to admission&#xD;
             to the clinical research site. An exception is made for hormonal contraceptives, which&#xD;
             may be used throughout the study.&#xD;
&#xD;
          -  All over-the-counter medication, vitamin preparations and other food supplements, or&#xD;
             herbal medications (eg, St. John's Wort) must have been stopped at least 14 days prior&#xD;
             to admission to the clinical research site.&#xD;
&#xD;
          -  Must be adequately informed and understand the nature and risks of the study and must&#xD;
             provide written informed consent prior to enrollment at screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who participate in one part of the study are not eligible to participate in&#xD;
             subsequent parts of the study.&#xD;
&#xD;
          -  Women who are pregnant, lactating, or planning to attempt to become pregnant during&#xD;
             this study or within 90 days after the follow-up visit.&#xD;
&#xD;
          -  Males with female partners who are planning to attempt to become pregnant during this&#xD;
             study or within 90 days after the follow-up visit.&#xD;
&#xD;
          -  History or evidence of significant clinical or psychiatric disorder, condition, or&#xD;
             disease that, in the opinion of the Investigator would pose an unacceptable risk to&#xD;
             the subject safety or interfere with the study evaluations, procedures, or completion&#xD;
             of the study.&#xD;
&#xD;
          -  Documented congenital QT syndrome, and/or corrected QT interval (Fridericia&#xD;
             correction; QTcF) at screening or first admission &gt; 450 ms.&#xD;
&#xD;
          -  Positive screening test for hepatitis B surface antigen, anti-hepatitis C virus&#xD;
             antibodies or anti-human immunodeficiency virus 1 and 2 antibodies.&#xD;
&#xD;
          -  History of drug allergy diagnosed by a physician.&#xD;
&#xD;
          -  Use of tobacco within 30 days prior to the first study drug administration.&#xD;
&#xD;
          -  History of alcohol consumption exceeding 2 standard drinks per day on average.&#xD;
&#xD;
          -  Routine or chronic use of more than 0.5 grams of acetaminophen daily.&#xD;
&#xD;
          -  History of donation of more than 450 mL of blood within 60 days prior to dosing in the&#xD;
             clinical research site or planned donation before 30 days has elapsed since intake of&#xD;
             study drug.&#xD;
&#xD;
          -  Plasma or platelet donation within 7 days of dosing&#xD;
&#xD;
          -  Use of any investigational drug or device within 30 days of the first dose of study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin Bunker, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Kalyra Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRA Health Sciences</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>March 5, 2019</study_first_submitted>
  <study_first_submitted_qc>March 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2019</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase I, Healthy Adult Participants</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxycodone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

